Protagonist Therapeutics (NASDAQ: PTGX) Price Target Raised to $180 Following Key FDA Approvals

• Analyst Optimism: Barclays raised Protagonist Therapeutics (NASDAQ: PTGX)'s price target to $180, indicating a potential 21.83% upside in the company's stock.
• FDA Approval Success: The biopharmaceutical company secured two U.S. Food and Drug Administration (FDA) approvals, including MIMRYLO for polycythemia vera, a first-in-class hepcidin mimetic.
• Financial Windfall: Strong Phase 3 trial results for MIMRYLO triggered a $275 million payment and potential future royalties and milestones up to $875 million from partner Takeda.

On September 1, 2026, an analyst from Barclays raised the price target for Protagonist Therapeutics (NASDAQ: PTGX) to $180. Protagonist Therapeutics is a biopharmaceutical company that develops new peptide-based medicines. It recently gained two U.S. Food and Drug Administration (FDA) approvals this year for drugs developed with partners Johnson & Johnson (NYSE: JNJ) and Takeda Pharmaceutical (NYSE: TAK).

The new $180 price target suggests a potential increase of about 21.83% from the stock's price of $147.75 when the target was set. This positive outlook follows significant news from PTGX. The company's stock has a 52-week range between $54.50 and $160.81 and a current market capitalization of approximately $9.50 billion.

A key driver for this optimism is the recent FDA approval of MIMRYLO. The drug treats erythrocytosis, which is the excessive production of red blood cells in adults with a rare blood cancer called polycythemia vera (PV). MIMRYLO is the first and only approved drug of its kind, known as a hepcidin mimetic.

As highlighted by Accesswire, the approval was based on strong Phase 3 trial results, where 76.9% of patients responded to the treatment. This milestone triggers a $275 million payment to PTGX. The company will also receive royalties, which are a percentage of sales, ranging from 14% to 29% from its partner Takeda.

Additionally, PTGX could earn up to $875 million more in future payments based on achieving other goals. Takeda is now fully responsible for selling the drug and its continued development. This allows PTGX to benefit financially while focusing on its other development programs.